文献速递产科母胎医学

妊娠期急性高血压急症中肼屈嗪与硝苯地平的比较:一项随机对照试验

Hydralazine vs nifedipine for acute hypertensive emergency in pregnancy: a randomized controlled trial.
PubMed 文献 · Am J Obstet Gynecol · 2017-09-01

这项双盲随机对照试验纳入60例妊娠≥24周、收缩压≥160 mmHg或舒张压≥110 mmHg的孕妇,比较静脉注射肼屈嗪与口服硝苯地平达到目标血压(收缩压150 mmHg、舒张压≤100 mmHg)的效果。两组达到目标血压的中位时间均为40分钟,中位给药次数均为2次,疗效相当;静脉注射肼屈嗪组呕吐发生率显著更高,两组均未发生严重母婴不良事件。

要点

  • 两组达到目标血压中位时间均为40分钟,中位给药次数均为2次,降压疗效相当。
  • 静脉注射肼屈嗪组呕吐发生率显著高于口服硝苯地平组(9/30 vs 2/30,P = .042)。
  • 两组均未观察到严重孕产妇或围产期不良事件。

核心结论

  • 静脉注射肼屈嗪与口服硝苯地平在妊娠期急性高血压急症的降压治疗中同样有效。

研究设计与样本

  • 双盲随机对照试验,自2014年12月至2015年9月共纳入60例妊娠≥24周且收缩压≥160 mmHg或舒张压≥110 mmHg的孕妇。
  • 受试者随机接受静脉注射肼屈嗪5、10、10、10 mg加安慰剂片,或口服硝苯地平10 mg片剂最多4次加静脉注射生理盐水,每20分钟给药一次,直至达到目标血压(收缩压150 mmHg、舒张压≤100 mmHg);初始治疗失败者接受交叉治疗。

主要发现

  • 两组达到目标血压的中位时间均为40分钟(四分位间距分别为5和40分钟,P = .809)。
  • 两组中位给药次数均为2次(四分位间距分别为1和2次,P = .625)。
  • 静脉注射肼屈嗪组呕吐发生率显著高于口服硝苯地平组(9/30 vs 2/30,P = .042)。
  • 两组均未观察到严重孕产妇或围产期不良事件。

关键数值与推荐

  • 主要结局为达到目标血压所需时间,两组中位时间均为40分钟(P = .809)。
  • 次要结局包括给药次数、母婴不良反应及围产期结局,两组中位给药次数均为2次(P = .625)。
  • 呕吐发生率静脉注射肼屈嗪组9/30 vs 口服硝苯地平组2/30(P = .042)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a paucity of good quality evidence regarding the best therapeutic option for acute control of blood pressure during acute hypertensive emergency of pregnancy. OBJECTIVE: We sought to compare the efficacy of intravenously administered hydralazine and oral nifedipine for acute blood pressure control in acute hypertensive emergency of pregnancy. STUDY DESIGN: In this double-blind, randomized, controlled trial, pregnant women (≥24 weeks period of gestation) with sustained increase in systolic blood pressure of ≥160 mm Hg or diastolic blood pressure of ≥110 mm Hg were randomized to receive intravenous hydralazine injection in doses of 5, 10, 10, and 10 mg and a placebo tablet or oral nifedipine (10 mg tablet up to 4 doses) and intravenous saline injection every 20 minutes until the target blood pressure of 150 mm Hg systolic and ≤100 mm Hg diastolic was achieved. Crossover treatment was administered if the initial treatment failed. The primary outcome of the study was time necessary to achieve target blood pressure. The secondary outcomes were the number of dosages required, adverse maternal and neonatal effects, and perinatal outcome. RESULTS: From December 2014 through September 2015, we enrolled 60 patients. The median time to achieve target blood pressure was 40 minutes in both groups (intravenous hydralazine and oral nifedipine) (interquartile interval 5 and 40 minutes, respectively, P = .809). The median dose requirement in both groups was 2 (intravenous hydralazine and oral nifedipine) (interquartile range 1 and 2 doses, respectively, P = .625). Intravenous hydralazine was associated with statistically significantly higher occurrence of vomiting (9/30 vs 2/30, respectively, P = .042). No serious adverse maternal or perinatal side effects were witnessed in either group. CONCLUSION: Both intravenous hydralazine and oral nifedipine are equally effective in lowering of blood pressure in acute hypertensive emergency of pregnancy.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Sharma C, Soni A, Gupta A, et al. Hydralazine vs nifedipine for acute hypertensive emergency in pregnancy: a randomized controlled trial. Am J Obstet Gynecol. 2017. PMID: 28867601. doi:10.1016/j.ajog.2017.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。